Amarantus BioScience President and CEO Publishes New Blog Entitled ''Continued Progress with our Business Plan in Central Nervous System Disorders''


Amarantus BioScience, Inc. (AMBS) today published a blog post entitled “Continued Progress with our Business Plan in Central Nervous System Disorders” on

Amarantus President and CEO, Gerald Commissiong, updates shareholders on an “aggressive growth strategy for the Company’s key products, MANF and LymPro.” Mr. Commissiong explains how the Company seeks to create multiple opportunities and mitigate risk in both of its Therapeutics and Diagnostics divisions. Read the full blog post from Gerald Commissiong on (

About Amarantus BioScience, Inc.

AmarantusBioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson’s disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information, please visit

About is an exclusive, online media publication where publically and privatively held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. In addition to management`s insightful blog posts, staff and aggregate partners contribute articles on finance, technology, health, and energy while providing updated market trends, news, and information.

View Comments (0)